Key Highlights

• Up to $8.8 Million Deal: Cadrenal Therapeutics (NASDAQ: CVKD) signed a private placement of up to $8.8 million with a single healthcare-focused institutional investor.

• $3 Million Upfront: The company receives $3 million upfront through 960,000 shares or pre-funded warrants, plus Series C-1 and C-2 warrants.

• H.C. Wainwright Placement Agent: H.C. Wainwright & Co. acted as exclusive placement agent, with warrants potentially adding $5.8 million if exercised for cash.

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) took a smaller and more structured route to raising capital. The company entered a definitive agreement with a single healthcare-focused institutional investor for a private placement of up to $8.8 million, priced at-the-market under Nasdaq rules.

The deal delivers $3 million upfront through the sale of 960,000 shares of common stock, or pre-funded warrants, together with accompanying Series C-1 and C-2 warrants. The combined purchase price is $3.125 per share and accompanying warrant.

If the warrants are fully exercised for cash, they could generate an additional $5.8 million in gross proceeds, bringing the total potential raise to $8.8 million. H.C. Wainwright & Co. acted as exclusive placement agent for the offering.

The structure is typical for micro-cap biotech. A modest upfront infusion addresses immediate funding needs, while the warrant coverage offers additional upside if the shares appreciate and the warrants are exercised. This approach avoids committing to a large equity block all at once and ties part of the proceeds to future share performance.

Pricing the placement at-the-market under Nasdaq rules is a common feature of these deals, keeping the transaction aligned with prevailing market levels. Using a single institutional investor can also streamline the process compared with a broad public offering.

For Cadrenal Therapeutics (NASDAQ: CVKD), the raise provides near-term operating flexibility. The key considerations for investors include how quickly the warrants might be exercised, the dilution associated with the full $8.8 million if realized, and how the company deploys the capital across its clinical priorities. Whether the warrants convert to cash depends largely on future share performance.